A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)

We are doing this research study to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC). Investigational means that the drug is not approved by any health authority, except for use in research studies like this. Osimertinib is approved by health authorities for treatment of NSCLC. Osimertinib is known to work well initially, but resistance often occurs after several months of treatment. The purpose of this study is to find out if administering savolitinib in combination with osimertinib will be a more effective treatment for NSCLC patients that have had disease progression while taking osimertinib alone.